Literature DB >> 8287597

Bone marrow transplantation therapy using resistant donors for retrovirus-induced leukaemia in mice.

H Iwai1, N K Day, N Hamada, M M Inaba, S Ikehara, R A Good.   

Abstract

Infection with Rauscher leukaemia virus (RLV) causes erythroleukaemia, anaemia, viraemia, and splenomegaly, features which develop very quickly in mice of strains susceptible to RLV but more slowly or not at all in strains resistant to RLV. We compared the effects of bone marrow transplantation (BMT) of donor cells obtained from a mouse strain resistant to the virus with the effects of BMT of donor cells obtained from strains susceptible to the virus, in recipient virus-susceptible mice which had previously been inoculated with RLV. Our results indicated that bone marrow transplantation from a marrow-resistant donor, but not from a susceptible donor, delayed the expression of leukaemia and delayed death, although such treatment did not appear to inhibit viral infection in susceptible recipients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8287597      PMCID: PMC1534632          DOI: 10.1111/j.1365-2249.1994.tb06027.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  27 in total

1.  QUANTITATION OF A MURINE LEUKEMIA VIRUS WITH A SPLEEN COLONY ASSAY.

Authors:  D H PLUZNIK; L SACHS
Journal:  J Natl Cancer Inst       Date:  1964-09       Impact factor: 13.506

Review 2.  Retrovirus-induced acquired immunodeficiencies.

Authors:  M Bendinelli; D Matteucci; H Friedman
Journal:  Adv Cancer Res       Date:  1985       Impact factor: 6.242

3.  Susceptibility of normal human lymphocytes to infection with HTLV-III/LAV.

Authors:  T Folks; J Kelly; S Benn; A Kinter; J Justement; J Gold; R Redfield; K W Sell; A S Fauci
Journal:  J Immunol       Date:  1986-06-01       Impact factor: 5.422

Review 4.  Human marrow transplantation: an immunological perspective.

Authors:  P J Martin; J A Hansen; R Storb; E D Thomas
Journal:  Adv Immunol       Date:  1987       Impact factor: 3.543

5.  HLA-associated susceptibility to acquired immunodeficiency syndrome in Italian patients with human-immunodeficiency-virus infection.

Authors:  R Scorza Smeraldi; G Fabio; A Lazzarin; N B Eisera; M Moroni; C Zanussi
Journal:  Lancet       Date:  1986-11-22       Impact factor: 79.321

6.  At least four viral genes contribute to the leukemogenicity of murine retrovirus MCF 247 in AKR mice.

Authors:  C A Holland; J W Hartley; W P Rowe; N Hopkins
Journal:  J Virol       Date:  1985-01       Impact factor: 5.103

7.  Eliminating human immunodeficiency virus (HIV) from infected individuals and cells: is it possible?

Authors:  D R O'Brien
Journal:  Med Hypotheses       Date:  1992-05       Impact factor: 1.538

8.  A phase I trial of recombinant human interferon-gamma in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome (AIDS).

Authors:  H C Lane; R T Davey; S A Sherwin; H Masur; A H Rook; J F Manischewitz; G V Quinnan; P D Smith; M E Easter; A S Fauci
Journal:  J Clin Immunol       Date:  1989-07       Impact factor: 8.317

9.  Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome.

Authors:  A H Rook; H Masur; H C Lane; W Frederick; T Kasahara; A M Macher; J Y Djeu; J F Manischewitz; L Jackson; A S Fauci; G V Quinnan
Journal:  J Clin Invest       Date:  1983-07       Impact factor: 14.808

10.  Leukemia prevention and long-term survival of AKR mice transplanted with MHC-matched or MHC-mismatched bone marrow.

Authors:  R E Longley; R A Good
Journal:  Cell Immunol       Date:  1986-09       Impact factor: 4.868

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.